Mymetics Corp (MYMX)

[Work Harder]

"Full length stabilized S receptor binding domain recombinant protein"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788321/

It will be interesting to see how the ongoing studies shift the focus between the full-length S-protein based and the RBD vaccines. The main argument in favor of the S-trimer is certainly the ambition to maintain the nature of the vaccine antigen as close to the natural confirmation as possible, while the interest in the RBD alone likely stems from concerns over adverse immune reactions triggered by full-length spike protein in SARS-CoV and also in RSV [62].

152. Kempers R. 2020. Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine. [Google Scholar] [Ref list]

Here

https://www.biospace.com/article/releases/mymetics-corporation-update/

Transvac 2

The virosome-based vaccine induces potent humoral and cellular immune responses critical in confronting life-threatening viral diseases. While RNA viruses mutate at high rates, virosomes can be versatile carriers that could develop multi-antigen epitopes against all strains of RNA viruses.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163346998

This vaccine will induce immune protection not only in the blood but will also elicit immune defense protection in the nasal and pulmonary mucous membranes and therefore aims to prevent transmission of the virus and infection at a very early stage before it spreads to other organs.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162351342

"The Swiss Mymetix Corporation (OTC: MYMX) follows the route through the nose. It shares intellectual property with major US corporation Catalent (NYSE: CTLT ) on how to pack antigenic material into virus-like particles (known as virosomes). The nasal vaccine is being developed with Baylor College of Texas and has shown promising results in animal studies."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163253848

Thanks to the posters

Ronald Kempers and the potential of a new COVID-19 nasal vaccine

https://www.biopole.ch/story/ronald-kempers-and-the-potential-of-a-new-covid-19-nasal-vaccine/

Have a good weekend folks